advertisement
Abstract #8712 Published in IGR 5-1
The efficacy and safety of the timolol/dorzolamide fixed combination versus latanoprost in exfoliation glaucoma
Konstas AGP; Kozobolis VP; Tersis I; Leech JN; Stewart WCEye 2003; 17: 41-46
PURPOSE: To evaluate the safety and efficacy of the timolol/dorzolamide fixed combination versus latanoprost 0.005% in exfoliation glaucoma patients. METHODS: The authors randomized, in an observer-masked fashion, 65 newly diagnosed exfoliation glaucoma patients to either timolol/dorzolamide twice daily or latanoprost daily treatment for two months, and then crossed these over to the other treatment. RESULTS: A total of 54 patients completed the study. After two months of chronic dosing, the morning intraocular pressure (IOP) (10:00) was reduced from a baseline of 31.2 ± 6.5 mmHg to 18.1 ± 3.0 with the fixed combination, and to 18.9 ± 4.1 mmHg with latanoprost (p = 0.21). Six patients discontinued both treatment periods early owing to inadequate IOP control, and two others discontinued latanoprost treatment only. The fixed combination showed a significantly greater incidence of taste distortion (p < 0.001) and stinging upon instillation (p = 0.036), while latanoprost showed a trend for increased conjunctival injection (p = 0.056). However, five patients demonstrated either bradycardia or asthmatic symptoms with initiation of the fixed combination therapy. One patient on latanoprost complained of dizziness. Patient preference was generally for latanoprost (63 versus 20.3%), mainly because of its once daily dosing (p < 0001). CONCLUSIONS: This study suggests that both latanoprost and the timolol/dorzolamide fixed combination are efficacious in the treatment of newly diagnosed exfoliation glaucoma.
Dr. A.G.P. Konstas, University Department of Ophthalmology AHEPA Hospital 1 Kyriakidi Street, Thessaloniki Greece. konstas@med.auth.gr
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
